EpiVacCorona
Key facts
- Drug.type
- vaccine
- Drug.image
- Фото упаковки ЭпиВакКороны.tif
- Drug.caption
- Package of EpiVacCorona vaccine
- Drug.target
- SARS-CoV-2
- Drug.vaccine_type
- peptide
- Drug.tradename
- EpiVacCorona
- Drug.legal_status
- Registered on 14 October 2020 Full list of EpiVacCorona authorizations
- Drug.routes_of_administration
- Intramuscular
- Drug.CAS_number
- 2695474-42-9
- Drug.ATC_prefix
- J07
- Drug.ATC_suffix
- BN
- Drug.DrugBank
- DB16439
Article
20 sectionsContents
- Pharmacology
- History
- Clinical trials
- Preclinical studies
- Clinical studies
- Phase I-II
- Phase III
- Study of vaccine effectiveness outside clinical trials
- Authorization
- Society and culture
- Economics
- Intellectual property
- Controversies
- Lack of effectiveness
- Independent study of clinical trial participants
- Vaccine criticism by independent experts
- Conflict of interest
- See also
- References
- External links
EpiVacCorona () is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology. The lack of protective effectiveness of EpiVacCorona, which is still in use in Russia, has been reported in scientific literature and in the media. The vaccine consists of three chemically synthesized peptides (short fragments of a viral spike protein) that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. A phase III clinical trial to show whether or not the vaccine can protect people against COVID-19 was launched in November 2020 with more than three thousand participants. The conclusions and results of the trial have not been made public.
Some experts in the field have expressed concerns about the selection of peptides for use as vaccine antigens. In addition, there are also serious concerns about the vaccine immunogenicity data, which have fueled independent civic research efforts and criticism by some experts. Current Time TV reported that "EpiVacCorona's reputation declined when vaccine trial participants sent an open letter to the Ministry of Health to flag 18 cases of COVID-19 infection among their group after vaccination with EpiVacCorona, and a lack of virus antibodies".